SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe E. who wrote (2170)10/7/1997 5:22:00 AM
From: Henry Niman   of 6136
 
Joe E. Thanks for the link. The data for Viracept seemed to be the studies described in AGPH's press release. The press release discussed 12 relatively naive patients and 7 more advanced as did the study described in your link. Its not clear who the 9 were in your upload, but since there were only 7 in the more advanced group, it had to contain some, if not all, of the more naive patients. The data seems to indicate that the prognosis for patients failing a PI is not good, but Viracept as the first PI may be slightly better than Crixivan. Even among the 12 relatively naive patients, viral load was not reduced to 500 copies in 2, and 4 of the 10 had viral counts going back up again in 4 months or less. Thus 50% of the relatively naive patients had 500 or more copies within 4 months of switching. The article also indicated that 50% of patients on PIs have had prior treatment with RTIs.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News